Nektar Therapeutics (NKTR) is having one of those days where the market and Wall Street analysts can't seem to agree on what just happened. The stock dropped over 7% Monday as investors continued processing mixed results from the company's Phase 2b trial for an alopecia treatment, even as analysts were busy raising their price targets.

The Trial Results: Close, But No Cigar

Here's the situation. Nektar's experimental drug rezpegaldesleukin was tested in severe alopecia areata patients, and while it showed proof-of-concept, it technically missed its primary endpoint when looking at all patients enrolled in the study.

In the intent-to-treat analysis, the treatment arms showed mean SALT score reductions of 28.2% and 30.3% compared to 11.2% for placebo. Sounds promising, right? The problem is those results weren't statistically significant, with p-values of 0.186 and 0.121 (anything above 0.05 typically doesn't make the cut).

But here's where it gets interesting. Nektar pointed out that when you exclude four patients who had major eligibility violations—meaning they probably shouldn't have been in the trial to begin with—both dosage arms actually achieved statistical significance. The company emphasized that the drug more than doubled placebo's treatment effect and announced plans to move into Phase 3 development in 2026.

Analysts See the Glass Half Full

Despite the sell-off, Wall Street is clearly focused on the adjusted numbers. BTIG maintained its Buy rating and bumped its price target from $100 to $118. H.C. Wainwright went even further, raising its target to $135 from $120—implying upside of more than 200% from current levels.

What's driving the optimism? Analysts appear encouraged by the drug's clean safety profile and its potential as a first-in-class Treg mechanism. They're viewing the adjusted data as validation that the drug works, headline miss notwithstanding.

The Technical Picture

Nektar shares closed Monday at $43.48, down 7.17%. The stock is currently trading 24% below its recent average price, reflecting considerable selling pressure. However, it's still sitting 38% above its longer-term average, which could provide a support level if the selling continues.

Interestingly, the stock maintains a high momentum score of 98.98, though short and medium-term trends remain unfavorable while the long-term outlook stays positive.